Abstract Number: 2548 • 2019 ACR/ARP Annual Meeting
Abatacept Failed to Demonstrate Efficacy in an SLE Trial with Low Placebo Response Rates, Although Global Assessments Indicated Less Flare Severity
Background/Purpose: Abatacept (ABA) is a fusion protein of the extracellular domain of CTLA4 and human IgG1-Fc, constructed to inhibit B/T cell co-stimulation. Previous studies of…Abstract Number: 2742 • 2019 ACR/ARP Annual Meeting
Toward a Liquid Biopsy for Lupus Nephritis: Urine Proteomic Analysis of SLE Identifies Inflammatory and Macrophage Signatures
Background/Purpose: Lupus nephritis (LN) complicates up to 60% of patients with systemic lupus erythematosus (SLE) and carries a high morbidity and mortality. The definitive diagnosis…Abstract Number: 9 • 2019 ACR/ARP Annual Meeting
Chemokine CXCL 10 Gene Expression as a Potential Activity Biomarker of Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by a wide range of systemic dysfunctions as well as an elevated erythrocyte sedimentation rate. Chemokine CXCL 10…Abstract Number: 246 • 2019 ACR/ARP Annual Meeting
Smoking Exposure in Pack-Years Predicts Cutaneous Manifestations of Lupus
Background/Purpose: Patients of color are more likely to have systemic lupus erythematosus (SLE) and a smoking history. Prior literature notes that both smoking and race…Abstract Number: 683 • 2019 ACR/ARP Annual Meeting
Biologic Differences Between Type 1 and 2 Lupus
Background/Purpose: The manifestations of systemic lupus erythematosus (SLE) can be divided into categories according to a recently proposed model: a category of classic active autoimmune-driven…Abstract Number: 944 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Dapirolizumab Pegol in Patients with Moderately to Severely Active Systemic Lupus Erythematosus: A Randomized, Placebo-Controlled Study
Background/Purpose: Dapirolizumab pegol (DZP) is a polyethylene glycol-conjugated Fab’ fragment, which targets CD40 ligand and is in development for the treatment of systemic lupus erythematosus…Abstract Number: 1104 • 2019 ACR/ARP Annual Meeting
Heritability and Familial Risk of Systemic Lupus Erythematosus in Sweden: A Population-based Case-control Study
Background/Purpose: Previous studies examining the relative risk (RR) associated with having a first degree relative (FDR) with systemic lupus erythematosus (SLE) were small and few…Abstract Number: 1569 • 2019 ACR/ARP Annual Meeting
Poor Long-term Renal Outcome in Systemic Lupus Erythematosus Without Abnormal Urinalysis: A Possible Link with Silent Lupus Nephritis
Background/Purpose: Background/Purpose: It has been well investigated that patients with lupus nephritis (LN) have worse prognosis than those without. Recently reported, about 20% of SLE…Abstract Number: 1610 • 2019 ACR/ARP Annual Meeting
Prediction of Organ Damage Accrual in Systemic Lupus Erythematosus Using a Frailty Index
Background/Purpose: We previously constructed a frailty index (FI) as a measure of susceptibility to adverse outcomes among patients with systemic lupus erythematosus (SLE). In this…Abstract Number: 1824 • 2019 ACR/ARP Annual Meeting
Perceived Stress Independently Associates with Worse Type 2 Symptoms in Systemic Lupus Erythematosus
Background/Purpose: A new posited framework for categorizing patients with systemic lupus erythematosus (SLE) is the division of symptomatology into two groups: type 1 manifestations represent…Abstract Number: 2032 • 2019 ACR/ARP Annual Meeting
Enhanced IFN a Production and STING Pathway in Monocytes in Systemic Lupus Erythematosus Is Suppressed by the Inhibition of mTOR Activation
Background/Purpose: Interferona (IFNa) is increased and plays an important role in the pathogenesis of systemic lupus erythematosus (SLE). Overexpression of type I IFN regulated genes…Abstract Number: 2517 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with…Abstract Number: 2552 • 2019 ACR/ARP Annual Meeting
Design and Development of an Online Intervention for Lupus Self-Management Based on the Transtheoretical Model of Change
Background/Purpose: The Lupus Foundation of America is in Year 4 of a 6-year cooperative agreement with the Centers for Disease Control and Prevention to develop…Abstract Number: 2780 • 2019 ACR/ARP Annual Meeting
Identification of SLE Subgroups at Risk for Poor Outcomes After Hydroxychloroquine Taper or Discontinuation
Background/Purpose: The risks and benefits of long-term hydroxychloroquine (HCQ) use in systemic lupus erythematosus (SLE), versus tapering or stopping, remain uncertain. We aimed to identify predictors of…Abstract Number: 67 • 2019 ACR/ARP Annual Meeting
Dermal Lymphatic Dysfunction Is Associated with Disease Activity in the MRL/lpr Lupus Model
Background/Purpose: Lymphatic vessels are important in limiting the extent and duration of peripheral immune response, both by transporting cellular debris, inflammatory cells and excess interstitial…
- « Previous Page
- 1
- …
- 104
- 105
- 106
- 107
- 108
- …
- 119
- Next Page »